Research Study Participants
Choosing to participate in a clinical research study is an important personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a study. After identifying study options, the next step is to contact the study research staff and ask questions about specific studies.
So, what is a clinical research study? Although there are many definitions of clinical research studies, they are generally considered to be biomedical or health-related research studies in human beings that follow a pre-defined protocol.
Additional Information:
Frequently Asked Questions
Choosing to participate in a clinicalÌýresearch studyÌýis an important personal decision. The following questions provide detailed information about participating in clinicalÌýresearch studies. In addition, it is often helpful to talk to a physician, family members, or friends about deciding to join a study.
Why participate in a clinicalÌýresearch study?ÌýParticipants in clinicalÌýresearch studies can play a more active role in their own health care, gain access to new research treatments before they are widely available, and help others by contributing to medical research.
Who can participate in a clinicalÌýresearch study?ÌýAll clinicalÌýresearch studies have guidelines about who can participate. Using inclusion/exclusion criteria is an important principle of medical research that helps to produce reliable results. The factors that allow someone to participate in a clinicalÌýresearch study are called "inclusion criteria" and that exclude someone from participating are called "exclusion criteria". These criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions.
Before joining a clinicalÌýresearch study, a participant must qualify for the study. Some research studies seek participants with illnesses or conditions to be studied in the clinicalÌýresearch study, while others need healthy participants. It is important to note that inclusion and exclusion criteria are not used to reject people personally. Instead, the criteria are used to identify appropriate participants and keep them safe. The criteria help ensure that researchers will be able to answer the questions they plan to study.
What are the benefits and risks of participating in a clinicalÌýresearch study?Ìý
µþ±ð²Ô±ð´Ú¾±³Ù²õÌýClinicalÌýresearch studies that are well-designed and well-executed are the best approach for eligible participants to:
- Play an active role in their own health care.
- Gain access to new research treatments before they are widely available.
- Obtain expert medical care at leading health care facilities during the trial.
- Help others by contributing to medical research
RisksÌýThere are risks to clinicalÌýresearch studies. There may be unpleasant, serious or even life-threatening side effects to an experimental treatment. The experimental treatment may not be effective for the participant. The protocol may require more of their time and attention than would a non-protocol treatment, including trips to the study site, more treatments, hospital stays or complex dosage requirements.
What are side effects and adverse reactions?ÌýSide effects are any undesired actions or effects of the experimental drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental treatments must be evaluated for both immediate and long-term side effects.
How is the safety of the participant protected?ÌýThe ethical and legal codes that govern medical practice also apply to clinicalÌýresearch studies. In addition, most clinical research is federally regulated with built in safeguards to protect the participants. The trial follows a carefully controlled protocol, a study plan which details what researchers will do in the study. As a clinicalÌýresearch study progresses, researchers report the results of the trial at scientific meetings, to medical journals, and to various government agencies. Individual participants' names will remain secret and will not be mentioned in these reports.
What kind of preparation should a potential participant make for the meeting with the research coordinator or doctor?
- Plan ahead and write down possible questions to ask.
- Ask a friend or relative to come along for support and to hear the responses to the questions.
Every clinicalÌýresearch study in the U.S. must be approved and monitored by an Institutional Review Board (IRB) to make sure the risks are as low as possible and are worth any potential benefits. An IRB is an independent committee of physicians, statisticians, community advocates, and others that ensures that a clinicalÌýresearch study is ethical and the rights of study participants are protected. All institutions that conduct or support biomedical research involving people must, by federal regulation, have an IRB that initially approves and periodically reviews the research.
Does a participant continue to work with a primary health care provider while in a clinicalÌýresearch study?ÌýYes. Most clinicalÌýresearch studies provide short-term treatments related to a designated illness or condition, but do not provide extended or complete primary health care. In addition, by having the health care provider work with the research team, the participant can ensure that other medications or treatments will not conflict with the protocol.
Can a participant leave a clinicalÌýresearch study after it has begun?ÌýYes. A participant can leave a clinicalÌýresearch study at any time. When withdrawing from the study, the participant should let the research team know about it, and the reasons for leaving the study. Leaving a study will not affect your current or future health care with the institution.Ìý
Who sponsors clinicalÌýresearch studies?ÌýClinicalÌýresearch studies are sponsored or funded by a variety of organizations or individuals such as physicians, medical institutions, foundations, voluntary groups, and pharmaceutical companies, in addition to federal agencies such as the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department of Veteran's Affairs (VA). Trials can take place in a variety of locations, such as hospitals, universities, doctors' offices, or community clinics.
Information is copyrightÌýÌý.
Questions to ask before participating in a clinicalÌýresearch study
What should people consider before participating in a clinicalÌýresearch study?
People should know as much as possible about the clinicalÌýresearch study and feel comfortable asking the members of the health care team questions about it, the care expected while in a study, and the cost of theÌýstudy. The following questions might be helpful for the participant to discuss with the health care team.
- What is the purpose of the study?
- Who is going to be in the study?
- How many volunteers are needed for the study?
- Why do researchers believe the experimental treatment being tested may be effective? Has it been tested before?
- Have there been otherÌýstudies similar to this one?
- What kinds of tests and experimental treatments are involved?
- How do the possible risks, side effects, and benefits in the study compare with my current treatment?
- How might this study affect my daily life?
- How long will theÌýstudy last?
- Will hospitalization be required?
- What are the standard treatment options for my condition if I choose not to participate?
- Who will pay for the experimental treatment?
- Will I incur any costs?
- Will I be reimbursed for other expenses or paid for my participation?
- What type of long-term follow up care is part of this study?
- How will I know that the experimental treatment is working? Will results of theÌýstudy be provided to me?
- Who will be in charge of my care?
- Whom should I contact if I have questions about the study?
Information is copyrightÌýÌý.
Glossary of Study Terms
The following glossary was prepared to help the consumer become familiar with many of the common terms used in clinicalÌýresearch studies.Ìý
Adverse ReactionÌýAn unwanted effect caused by the administration of drugs. Onset may be sudden or develop over time.
ÌýAdvocacy and Support GroupsÌýOrganizations and groups that actively support participants and their families with valuable resources, including self-empowerment and survival tools.Ìý
Approved DrugsÌýIn the U.S., the Food and Drug Administration (FDA) must approve a substance as a drug before it can be marketed. The approval process involves several steps including pre-clinical laboratory and animal studies, clinical trials for safety and efficacy, filing of a New Drug Application by the manufacturer of the drug, FDA review of the application, and FDA approval/rejection of application.Ìý
AssentÌýA minor's agreement to participate in a clinical research study.Ìý
ArmsÌýAny of the treatment groups in a randomizedÌýstudy. Most randomized studies have two "arms," but some have three "arms," or even more.Ìý
BaselineÌý1. Information gathered at the beginning of a study from which variations found in the study are measured. 2. A known value or quantity with which an unknown is compared when measured or assessed. 3. The initial time point in a clinical trial, just before a participant starts to receive the experimental treatment which is being tested. At this reference point, measurable values such as CD4 count are recorded. Safety and efficacy of a drug are often determined by monitoring changes from the baseline values.Ìý
BiasÌýWhen a point of view prevents impartial judgment on issues relating to the subject of that point of view. In clinical studies, bias is controlled by blinding and randomization.Ìý
BlindÌýA randomizedÌýclinical research studyÌýis "Blind" if the participant is not told which arm of the trial he is on. A clinical research study is "Blind" if participants are unaware on whether they are in the experimental or control arm of the study; also called masked.Ìý
ClinicalÌýPertaining to or founded on observation and treatment of participants, as distinguished from theoretical or basic science.Ìý
Clinical InvestigatorÌýA medical researcher in charge of carrying out a clinical trial's protocol.
Clinical Research CoordinatorÌýA person who helps the investigator run a clinical study.Ìý Also called a “Study Coordinatorâ€� or “Nurse Coordinatorâ€�.Ìý
Clinical Research StudyÌýA clinicalÌýresearchÌýstudyÌýis a research study to answer specific questions about vaccines or new therapies or new ways of using known treatments. ClinicalÌýresearchÌýstudies are used to determine whether new drugs or treatments are both safe and effective. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people. Trials are in four phases: Phase I tests a new drug or treatment in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people; and Phase IV takes place after the drug or treatment has been licensed and marketed.Ìý
CohortÌýIn epidemiology, a group of individuals with some characteristics in common.Ìý
Community Based ClinicalÌýResearchÌýStudy (CBCT)ÌýA clinicalÌýresearchÌýstudy conducted primarily through primary-care physicians rather than academic research facilities.Ìý
Compassionate UseÌýA method of providing experimental therapeutics prior to final FDA approval for use in humans. This procedure is used with very sick individuals who have no other treatment options. Often, case-by-case approval must be obtained from the FDA for "compassionate use" of a drug or therapy.Ìý
Complementary and Alternative TherapyÌýBroad range of healing philosophies, approaches, and therapies that Western (conventional) medicine does not commonly use to promote well-being or treat health conditions. Examples include acupuncture, herbs, etc.Ìý
Confidentiality Regarding ClinicalÌýResearch StudyÌýParticipantsÌýRefers to maintaining the confidentiality of trial participants including their personal identity and all personal medical information. The trial participants' consent to the use of records for data verification purposes should be obtained prior to the trial and assurance must be given that confidentiality will be maintained.Ìý
ContraindicationÌýA specific circumstance when the use of certain treatments could be harmful.Ìý
ControlÌýA control is the nature of the intervention control.Ìý
Control GroupÌýThe standard by which experimental observations are evaluated. In many clinicalÌýresearchÌýstudies, one group of patients will be given an experimental drug or treatment, while the control group is given either a standard treatment for the illness or a placebo.Ìý
Controlled ClinicalÌýResearchÌýStudies Control is a standard against which experimental observations may be evaluated. In clinicalÌýresearchÌýstudies, one group of participants is given an experimental drug, while another group (i.e., the control group) is given either a standard treatment for the disease or a placebo.Ìý
Data Safety and Monitoring Board (DSMB)ÌýAn independent committee, composed of community representatives and clinical research experts, that reviews data while a clinical trial is in progress to ensure that participants are not exposed to undue risk. A DSMB may recommend that a trial be stopped if there are safety concerns or if the trial objectives have been achieved.Ìý
Diagnostic ClinicalÌýResearchÌýStudiesÌýRefers toÌýresearch studiesÌýthat are are conducted to find better tests or procedures for diagnosing a particular disease or condition. Diagnostic studies usually include people who have signs or symptoms of the disease or condition being studied.Ìý
Dose-Ranging StudyÌýA clinicalÌýresearchÌýstudy in which two or more doses of an agent (such as a drug) are tested against each other to determine which dose works best and is least harmful.Ìý
Double-Blind StudyÌýA clinicalÌýresearchÌýstudy design in which neither the participating individuals nor the study staff knows which participants are receiving the experimental drug and which are receiving a placebo (or another therapy). Double-blind trials are thought to produce objective results, since the expectations of the doctor and the participant about the experimental drug do not affect the outcome; also called double-masked study.Ìý
Drug-Drug InteractionÌýA modification of the effect of a drug when administered with another drug. The effect may be an increase or a decrease in the action of either substance, or it may be an adverse effect that is not normally associated with either drug.Ìý
EfficacyÌý(Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the procedure mandated by the FDA, Phase II clinical trials gauge efficacy, and Phase III trials confirm it.Ìý
Eligibility CriteriaÌýSummary criteria for participant selection; includes Inclusion and Exclusion criteria.
EmpiricalÌýBased on experimental data, not on a theory.Ìý
EndPointÌýOverall outcome that the protocol is designed to evaluate. Common endpoints are severe toxicity, disease progression, or death.Ìý
EnrollingÌýThe act of signing up participants into a study. Generally this process involves evaluating a participant with respect to the eligibility criteria of the study and going through the informed consentÌýprocess.ÌýÌý
EpidemiologyÌýThe branch of medical science that deals with the study of incidence and distribution and control of a disease in a population.Ìý
Expanded AccessÌýRefers to any of the FDA procedures, such as compassionate use, parallel track, and treatment IND that distribute experimental drugs to participants who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinicalÌýresearchÌýstudies.Ìý
Experimental DrugÌýA drug that is not FDA licensed for use in humans, or as a treatment for a particular condition.Ìý
Food and Drug Administration (FDA)ÌýThe U.S. Department of Health and Human Services agency responsible for ensuring the safety and effectiveness of all drugs, biologics, vaccines, and medical devices, including those used in the diagnosis, treatment, and prevention of HIV infection, AIDS, and AIDS-related opportunistic infections. The FDA also works with the blood banking industry to safeguard the nation's blood supply.Ìý
HypothesisÌýA supposition or assumption advanced as a basis for reasoning or argument, or as a guide to experimental investigation.Ìý
Inclusion/Exclusion CriteriaÌýThe medical or social standards determining whether a person may or may not be allowed to enter a clinicalÌýresearchÌýstudy. These criteria are based on such factors as age, gender, the type and stage of a disease, previous treatment history, and other medical conditions. It is important to note that inclusion and exclusion criteria are not used to reject people personally, but rather to identify appropriate participants and keep them safe.Ìý
Informed ConsentÌýThe process of learning the key facts about a clinicalÌýresearchÌýstudy before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study.Ìý
Informed Consent DocumentÌýA document that describes the rights of the study participants, and includes details about the study, such as its purpose, duration, required procedures, and key contacts. Risks and potential benefits are explained in the informed consent document. The participant then decides whether or not to sign the document. Informed consent is not a contract, and the participant may withdraw from the clinicalÌýresearchÌýstudy at any time.Ìý
Institutional Review Board (IRB)1. A committee of physicians, statisticians, researchers, community advocates, and others that ensures that a clinicalÌýresearchÌýstudy is ethical and that the rights of study participants are protected. All clinical trials in the U.S. must be approved by an IRB before they begin. 2. Every institution that conducts or supports biomedical or behavioral research involving human participants must, by federal regulation, have an IRB that initially approves and periodically reviews the research in order to protect the rights of human participants.Ìý
Intent To TreatÌýAnalysis of a clinicalÌýresearchÌýstudy results that includes all data from participants in the groups to which they were randomized even if they never received the treatment.Ìý
Intervention NameÌýThe generic name of the precise intervention being studied.Ìý
InterventionsÌýPrimary interventions being studied: types of interventions are Drug, Gene Transfer, Vaccine, Behavior, Device, or Procedure.Ìý
Investigational New DrugÌýA new drug, antibiotic drug, or biological drug that is used in a clinical investigation. It also includes a biological product used in vitro for diagnostic purposes.Ìý
MaskedÌýThe knowledge of intervention assignment.Ìý
Natural History StudyÌýStudy of the natural development of something (such as an organism or a disease) over a period of time.Ìý
New Drug Application (NDA)ÌýAn application submitted by the manufacturer of a drug to the FDA - after clinicalÌýresearchÌýstudies have been completed - for a license to market the drug for a specified indication.Ìý
Off-Label UseÌýA drug prescribed for conditions other than those approved by the FDA.ÌýÌý
Open-Label ClinicalÌýResearchÌýStudyÌýA clinicalÌýresearchÌýstudy in which doctors and participants know which drug or vaccine is being administered.Ìý
Orphan DrugsÌýAn FDA category that refers to medications used to treat diseases and conditions that occur rarely. There is little financial incentive for the pharmaceutical industry to develop medications for these diseases or conditions. Orphan drug status, however, gives a manufacturer specific financial incentives to develop and provide such medications.
ParticipantÌýOne who participates in a clinical research study
Peer ReviewÌýReview of a clinicalÌýresearchÌýstudy by experts chosen by the study sponsor. These experts review theÌýstudies for scientific merit, participant safety, and ethical considerations.Ìý
PharmacokineticsÌýThe processes (in a living organism) of absorption, distribution, metabolism, and excretion of a drug or vaccine.Ìý
Phase I TrialsÌýInitial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.Ìý
Phase II Trials Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks.ÌýÌý
Phase III TrialsÌýExpanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide and adequate basis for physician labeling.ÌýÌý
Phase IV TrialsÌýPost-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use.ÌýÌý
PlaceboÌýA placebo is an inactive pill, liquid, or powder that has no treatment value. In clinical trials, experimental treatments are often compared with placebos to assess the treatment's effectiveness.Ìý
Placebo Controlled StudyÌýA method of investigation of drugs in which an inactive substance (the placebo) is given to one group of participants, while the drug being tested is given to another group. The results obtained in the two groups are then compared to see if the investigational treatment is more effective in treating the condition.Ìý
Placebo EffectÌýA physical or emotional change, occurring after a substance is taken or administered, that is not the result of any special property of the substance. The change may be beneficial, reflecting the expectations of the participant and, often, the expectations of the person giving the substance.Ìý
PreclinicalÌýRefers to the testing of experimental drugs in the test tube or in animals - the testing that occurs before trials in humans may be carried out.Ìý
Prevention ClinicalÌýResearchÌýStudiesÌýRefers to trials to find better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes.Ìý
ProtocolÌýA study plan on which all clinicalÌýresearchÌýstudies are based. The plan is carefully designed to safeguard the health of the participants as well as answer specific research questions. A protocol describes what types of people may participate in the trial; the schedule of tests, procedures, medications, and dosages; and the length of the study. While in a clinical trial, participants following a protocol are seen regularly by the research staff to monitor their health and to determine the safety and effectiveness of their treatment.Ìý
Quality of Life ClinicalÌýResearchÌýStudiesÌýRefers to studies that explore ways to improve comfort and quality of life for individuals with a chronic illness.Ìý
RandomizationÌýA method based on chance by which study participants are assigned to a treatment group. Randomization minimizes the differences among groups by equally distributing people with particular characteristics among all the trial arms. The researchers do not know which treatment is better. From what is known at the time, any one of the treatments chosen could be of benefit to the participant.Ìý
Randomized ClinicalÌýResearchÌýStudyÌýA study in which participants are randomly (by chance) assigned to one of two or more treatment arms of a clinicalÌýresearchÌýstudy. Occasionally placebos are utilized.Ìý
RecruitingÌýThe period during which aÌýstudy is attempting to identify and enroll participants. Recruitment activities can include advertising and other ways of soliciting interest from possible participants.Ìý
Recruitment StatusÌýIndicates the current stage of a study, whether it is planned, ongoing, or completed. Possible values include:
- Not yet recruiting: participants are not yet being recruited or enrolled
- Recruiting: participants are currently being recruited and enrolled
- Enrolling by invitation: participants are being (or will be) selected from a predetermined population
- Active, not recruiting: study is ongoing (i.e., patients are being treated or examined), but enrollment has completed
- Completed: the study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred)
- Suspended: recruiting or enrolling participants has halted prematurely but potentially will resume
- Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
- Withdrawn: study halted prematurely, prior to enrollment of first participant
Risk-Benefit RatioÌýThe risk to individual participants versus the potential benefits. The risk/benefit ratio may differ depending on the condition being treated.Ìý
Screening ClinicalÌýResearchÌýStudiesÌýRefers to studies which test the best way to detect certain diseases or health conditions.Ìý
Side EffectsÌýAny undesired actions or effects of a drug or treatment. Negative or adverse effects may include headache, nausea, hair loss, skin irritation, or other physical problems. Experimental drugs must be evaluated for both immediate and long-term side effects.Ìý
Single-Blind StudyÌýA study in which one party, either the investigator or participant, is unaware of what medication the participant is taking; also called single-masked study.Ìý
Standard TreatmentÌýA treatment currently in wide use and approved by the FDA, considered to be effective in the treatment of a specific disease or condition.ÌýÌý
Standards of CareÌýTreatment regimen or medical management based on state of the art participant care.Ìý
Statistical SignificanceÌýThe probability that an event or difference occurred by chance alone. In clinical trials, the level of statistical significance depends on the number of participants studied and the observations made, as well as the magnitude of differences observed.Ìý
Study EndpointÌýA primary or secondary outcome used to judge the effectiveness of a treatment.Ìý
Study TypeÌýThe primary investigative techniques used in an observational protocol; types are Purpose, Duration, Selection, and Timing.Ìý
ToxicityÌýAn adverse effect produced by a drug that is detrimental to the participant's health. The level of toxicity associated with a drug will vary depending on the condition which the drug is used to treat.Ìý
Treatment INDÌýIND stands for Investigational New Drug application, which is part of the process to get approval from the FDA for marketing a new prescription drug in the U.S. It makes promising new drugs available to desperately ill participants as early in the drug development process as possible. Treatment INDs are made available to participants before general marketing begins, typically during Phase III studies. To be considered for a treatment IND a participant cannot be eligible to be in the definitive clinical trial.Ìý
Treatment ClinicalÌýResearchÌýStudy Refers to studies which test new treatments, new combinations of drugs, or new approaches to surgery or radiation therapy.
Information is copyrightÌýÌý.
Additional InformationÌýabout ClinicalÌýResearch Studies
- NIH Registry of Clinical Trials:Ìý
- National Cancer Institute:Ìý
- Center for Information and Study on Clinical Research Participation:Ìý
- NIH and Clinical Trials:Ìý